{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:29:36Z","timestamp":1787758176683,"version":"build-2784847793"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Asciminib, a \u201cSpecifically Targeting the ABL Myristoyl Pocket\u201d inhibitor, is a new drug in the treatment of tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML). Hemocytopenias associated with asciminib are common adverse events documented by clinical trials. We report a case of precipitous-onset pancytopenia with the initiation of asciminib treatment in a patient with TKI-resistant CML. This case had a confounding array of laboratory findings that evidenced a drug-induced hemophagocytic component. We hope that our case stimulates further reporting of similar cases to enhance the understanding of the pathophysiology underlying asciminib-induced hemocytopenias.<\/jats:p>","DOI":"10.4103\/ijciis.ijciis_85_22","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T06:41:34Z","timestamp":1687934494000},"page":"78-81","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia"],"prefix":"10.4103","volume":"13","author":[{"given":"Steven","family":"Tessier","sequence":"first","affiliation":[{"name":"Department of Medicine, St. Luke\u2019s University Health Network, Bethlehem, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Aiad","sequence":"additional","affiliation":[{"name":"Department of Medicine, St. Luke\u2019s University Health Network, Bethlehem, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo","family":"Longo","sequence":"additional","affiliation":[{"name":"Department of Pathology, St. Luke\u2019s University Health Network, Bethlehem, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, St. Luke\u2019s University Health Network, Bethlehem, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacoub","family":"Faroun","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, St. Luke\u2019s University Health Network, Bethlehem, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"issue":"1038\/s41375-022-01736-5","key":"R1-20240902","article-title":"Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia [published online ahead of print,","volume":"10","author":"Senapati","year":"2022","journal-title":"Leukemia"},{"key":"R2-20240902","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia:10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"R3-20240902","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"R4-20240902","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk Res"},{"key":"R5-20240902","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open.label, randomized study of asciminib, a STAMP inhibitor, versus bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"R6-20240902","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"R7-20240902","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00277-022-04932-6","article-title":"Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia","volume":"101","author":"Luna","year":"2022","journal-title":"Ann Hematol"},{"key":"R8-20240902","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-021-00420-8","article-title":"Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice","volume":"11","author":"Garcia-Guti\u00e9rrez","year":"2021","journal-title":"Blood Cancer J"},{"key":"R9-20240902","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11523-011-0202-9","article-title":"Hematologic toxicities of small molecule tyrosine kinase inhibitors","volume":"6","author":"Barber","year":"2011","journal-title":"Target Oncol"},{"key":"R10-20240902","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/bcp.13933","article-title":"Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia:A network meta-analysis","volume":"85","author":"Fachi","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R11-20240902","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20240902","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/asheducation-2009.1.127","article-title":"Hemophagocytic lymphohistiocytosis (HLH) and related disorders","author":"Filipovich","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R13-20240902","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/10428194.2021.1992623","article-title":"The prevalence and prognosis of hyponatraemia in non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis","volume":"63","author":"Yin","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R14-20240902","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["International Journal of Critical Illness and Injury Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijciis.ijciis_85_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:05:26Z","timestamp":1787756726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijciis.ijciis_85_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijciis.ijciis_85_22","relation":{},"ISSN":["2229-5151","2231-5004"],"issn-type":[{"value":"2229-5151","type":"print"},{"value":"2231-5004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2022-12-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}